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140 gB mRNA vaccinated rabbits had slightly reduced total peptide binding compared to gB FL 141 (Figure 3B ; median peptide-binding MFI sum: FL = 96,629, mRNA = 48,051, p=ns, Kruskal-Wallis 142 + post hoc Mann-Whitney U test), though both gB FL and gB mRNA had greater total peptide 143 binding than the gB ecto group (both p<0.05, Kruskal-Wallis + post hoc Mann-Whitney U test).
144 Importantly, there was enhanced breadth of peptide-binding responses in gB mRNA vaccinated 145 rabbits compared to both gB FL and gB ecto groups (Figure 3D ; median number of discrete 146 peptides bound: FL = 44.5, ecto = 28.5, mRNA = 85, both p<0.05, Kruskal-Wallis + post hoc 147 Mann-Whitney U test). Of note, the pattern of linear peptide binding and breadth of mRNA-148 immunized rabbits appears analogous to that elicited by natural HCMV infection [18] .
150 Vaccine-elicited IgG binding to neutralizing epitopes and HCMV neutralization 151
We next examined IgG binding to regions of gB known to be targeted by neutralizing 152 antibodies Domain 1 (AD-4), Domain 1+2 (AD-4 + AD-5), AD-1, and AD-2 ( Figure 4A-D) . Notably, 153 we did not identify vaccine-elicited antibodies against AD-2 in any of the 3 vaccine groups ( Figure   154 4D) , an epitope known to be the target of potently-neutralizing gB-specific antibodies associated 155 with reduced viremia in transplant recipients [19] and protection against congenital transmission 156 [20]. Furthermore, low responses were noted against AD-1 ( Figure 4C) . The kinetics of vaccine-254 though the precise mechanism remains unknown. Lastly, HCMV-specific CD4 + 
257
Given the uncertainty regarding precise epitope specificities or immune effector functions 258 protective against HCMV-associated disease, we regarded enhanced durability and breadth of 259 immune responses as desirable attributes for vaccine development and the primary outcomes of 260 interest in this study. Overall, we identified that the experimental vaccines (gB FL, gB ecto, and 276 Importantly, while HCMV gB mRNA vaccines have been tested previously in a preclinical model 277 [48] , this is the first such investigation to test a gB mRNA-based vaccine alongside the partially-278 effective gB/MF59 protein subunit vaccination and to directly compare the epitope specificity, 279 durability, and neutralizing/non-neutralizing function of antibodies elicited by these two vaccine 280 platforms.
281
In this investigation, we specifically focused on the implications of the gB/MF59-elicited 282 immune-dominant response directed against gB AD-3 [25]. We hypothesized the absence of 283 neutralizing antibodies in gB/MF59 vaccinees may be attributable to the dominant responses 284 against the AD-3 'decoy epitope', which diverted antibody targeting away from 'more functional' 285 epitopes [24] . We directly tested this hypothesis with our gB ecto group by excluding AD-3 from 286 the immunogen. Intriguingly, we failed to see any consistent increase in the magnitude of 287 functional neutralizing/non-neutralizing antibodies in gB ecto vaccinated rabbits, suggesting that 288 inclusion of the AD-3 epitope in the vaccine immunogen does not hinder the development of more 289 functional antibodies. Is it therefore possible that AD-3 directed antibodies have any functional or 290 protective role that might account for the 50% vaccine efficacy observed in gB/MF59 vaccinees?
291 In this study we noted that AD-3-specific antibodies can mediate non-neutralizing antibody 292 effector functions including whole virion phagocytosis (Figure 6) . Consequently, the high-293 magnitude AD-3 response in gB FL-vaccinated rabbits likely accounts for our observation of 294 robust and durable phagocytosis activity in these animals (Figure 5E ).
295
A limitation to this study is dissimilarity in vaccine dose and route of delivery between 296 comparison groups. Protein subunit vaccines (gB FL, gB ecto) were given I.M. at a dose of 20µg, 297 mimicking the protocol for gB/MF59 immunized humans in the partially-efficacious clinical trials 298 [12, 13, 24] . In contrast, 50µg of the gB nucleoside-modified mRNA-LNP was administered I.D, 299 which was selected because this delivery method enhances protein expression in vivo [49] .
300 Depending on the antigen and vaccine formulation, intradermal vaccination may be as much as 301 10 times more potent than intramuscular dosing [50] . Therefore, we cannot rule out the possibility 302 that our results of enhanced breadth and durability in gB mRNA-immunized rabbits are 303 dose/method dependent -that a higher dose or different delivery method of gB FL protein might 304 not have achieved similar results to gB mRNA-LNP vaccinated rabbits. Furthermore, while rabbits 305 provide an excellent model to study vaccine immunogenicity, this investigation was restricted by 306 the rabbit immunologic toolbox. We were able to measure F c γ receptor engagement in this study, 307 though lacked the ability to identify the mechanism behind variable F c γ receptor engagement (e.g.
308 IgG subclass or F c glycosylation). Furthermore, while we were able to identify gB-specific T cells 309 in spleen, we were unable to: 1) identify antigen-specific T cells in peripheral blood, and 2) parse 310 out T cell subsets (CD4 + , CD8 + , etc). Nevertheless, the results described are sufficient justification 311 for subsequent testing of the gB mRNA-LNP vaccine in nonhuman primate preclinical challenge 312 models and/or human clinical trials.
313
This comparison of immune responses elicited by next-generation HCMV vaccines, head-314 to-head against gB/MF59 immunization (gB FL), provides a basis for rational gB vaccine 315 development efforts. First, we have demonstrated that gB nucleoside-modified mRNA-LNP 316 immunization improves the durability of gB-binding and functional antibody responses and 317 enhances the breadth of the gB-specific antibody repertoire. Additionally, we note that gB 318 ectodomain immunization did not elicit antibody responses that were functionally superior to gB 319 FL, suggesting that the immunodominant AD-3 response does not interfere with the development 320 of functional antibodies. While we await well-validated immune correlates of protection to inform 321 HCMV vaccine development efforts, the gB mRNA-LNP vaccine clearly had enhanced long-term 322 immunogenicity and response breadth compared with gB FL and gB ecto vaccines. Therefore, 323 we propose subsequent testing of this vaccine platform in nonhuman primate challenge models 324 as well as human immunogenicity trials to rigorously interrogate its ability to elicit immune factors 325 protective against congenital HCMV infection and transplant-associated disease. 585 food supplements, interaction with caregivers and research staff). All protocols were reviewed 586 and approved by the Duke University Animal Care and Use Committee (IACUC) prior to the 587 initiation of the study (protocol #A314-15-12).
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